Freeze-drying of nanosuspensions, part 3: Investigation of factors compromising storage stability of highly concentrated drug nanosuspensions

Journal of Pharmaceutical Sciences

Volumn 101, Issue 1, 2012, Pages 354-362

  Beirowski, Jakob ^a   Inghelbrecht, Sabine ^b   Arien, Albertina ^b   Gieseler, Henning ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Calorimetry; Freeze drying; Lyophilization; Milling; Nanoparticles; Nanosuspensions; Nanotechnology; Parenterals; Stability

Indexed keywords

CREMOPHOR; NANOPARTICLE; POLOXAMER; POVIDONE; SUCROSE; TREHALOSE;

ARTICLE; FREEZE DRYING; PARTICLE SIZE; STORAGE; SUSPENSION; WATER CONTENT;

EID: 82255162783     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22745     Document Type: Article

References (25)

1. Franks F. 1998. Freeze-drying of bioproducts: Putting principles into practice. Eur J Pharm Biopharm 45:221-229.
2. Wang W. 2000. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 203:1-60.
3. Pikal MJ, Costantino MR. 2004. Lyophilization of biopharmaceuticals. In Biotechnology: Pharmaceutical aspects; Borchardt RT, Middaugh CR, Eds. Arlington: AAPS, pp 1-75.
4. Tang XC, Pikal MJ. 2004. Design of freeze-drying processes for pharmaceuticals: Practical advice. Pharm Res 21(2):191-200.
5. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. 2006. Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv Drug Deliv Rev 58(15):1688-1713.
6. Beirowski J, Inghelbrecht S, Arien A, Gieseler H. 2011. Freeze-drying of nanosuspensions, 1: Freezing rate versus formulation design as critical factors to preserve the original particle size distribution. J Pharm Sci 100(5):1958-1968.
7. Merisko-Liversidge E, Liversidge GG, Cooper ER. 2003. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18(2):113-120.
8. Gao L, Zhang D, Chen M. 2008. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res 10:845-862.
9. Kesisoglou F, Panmai S, Wu Y. 2007. Nanosizing-Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 59:631-644.
10. Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B, Kipp J, Ning J. 2008. Suspensions for intravenous (IV) injection: A review of development, clinical and preclinical aspects. Adv Drug Deliv Rev 60:939-954.
11. Beirowski J, Inghelbrecht S, Arien A, Gieseler H. 2009. Investigation of various Poloxamers as freeze-drying stabilizers in freeze-drying of nanosuspensions. Frankfurt/Main, Germany: Proc. Parent Drug Association.
12. Beirowski J, Inghelbrecht S, Arien A, van Assche I, Gieseler H. 2010. Stabilization of nanosuspensions during freeze-drying: The role of vitrification (Part 1). Valetta, Malta, March 8-11: Proc. 7th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology.
13. Beirowski J, Inghelbrecht S, Arien A, van Assche I, Gieseler H. 2010. Stabilization of nanosuspensions during freeze-drying: The role of vitrification and its practical implications (Part 2). Valetta, Malta, March 8-11: Proc. 7th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology.
14. Beirowski J, Inghelbrecht S, Arien A, Gieseler H. 2011. Freeze-Drying of Nanosuspensions, 2: The Role of the Critical Formulation Temperature on Stability of Drug-Nanosuspensions and Its Practical Implication on Process Design. J Pharm Sci [Article first published online: 23 MAY 2011]
15. Merisko-Liversidge E, Sarpotdar P, Bruno J, Hajj S, Wei L, Peltier N, Rake J, Shaw J M, Pugh S, Polin L Jones J, Corbett T, Cooper E, Liversidge GG. 1996. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res 13:272-278.
16. Mouton JW, van Peer A, de Beule K, van Vliet A, Donnelly JP, Soons PA. 2006. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 50:4096-4102.
17. Wahlstrom JL, Chiang PC, Ghosh S, Warren CJ, Wene SP, Albin LA, Smith ME, Roberds SL. 2007. Pharmacokinetic evaluation of a 1, 3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment. Nanoscale Res Lett 2:291-296.
18. Chiang PC, Wahlstrom JL, Selbo JG, Zhou S, Wene SP, Albin LA, Warren CJ, Smith ME, Roberds SL, Ghosh S, Zhang LL, Pretzer DK. 2007. 1, 3-dicyclohexylurea nanosuspension for intraveneous steady-state delivery in rats. J Exp Nanosci 2:239-250.
19. Kumar MP, Rao YM, Apte S. 2007. Improved bioavailability of albendazole following oral administration of nanosuspension in rats. Curr Nanosci 3:191-194.
20. Kumar MP, Rao YM, Apte S. 2008. Formulations of nanosuspensions of albendazole for oral administration. Curr Nanosci 4:53-58.
21. Grimm W. 1998. Extension of the International Conference on Harmonization tripartite guideline for stability testing of new drug substances and products to countries of climatic zones III and IV. Drug Dev Ind Pharm 24(4):313-325.
22. Lee J, Cheng Y. 2006. Critical freezing rate in freeze drying nanocrystal dispersions. J Control Release 111:185-192.
23. Beirowski J, Gieseler H. 2008. Application of DSC and MDSC in the development of freeze-dried pharmaceuticals. Eur Pharm Rev 13(6):63-70.
24. Pikal MJ. 1998. Mechanisms of protein stabilization during freeze-drying and storage: The relative importance of thermodynamic relaxation and glassy state relaxation dynamics. In Freeze-drying/lyophilization of pharmaceuticals and biological products 96; Rey L, May LC, Eds. New York: Marcel Dekker, pp 161-198.
25. Allison SD, Molina MDC, Anchordoquy TJ. 2000. Stabilization of lipid/DNA complexes during the freezing step of the lyophilization process: The particle isolation hypothesis. Biochim Biophys Acta 1468:127-138.